Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta-analysis.","authors":"Marina Mordehachvili Burlá, Izabela Pera Calvi, Regina Chahine Chater, Rafaela de Moraes-Souza, Vladimir V Rafalskiy, Pedro Herranz-Pinto, George Doumat, Maria Tsoukas, Roger Haber","doi":"10.1111/jdv.20418","DOIUrl":"https://doi.org/10.1111/jdv.20418","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing HFUS accuracy in melanoma assessment: The role of artificial intelligence and statistical precision.","authors":"I Chen, S Yu","doi":"10.1111/jdv.20419","DOIUrl":"https://doi.org/10.1111/jdv.20419","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail clipping may not be sufficient to corroborate the diagnosis of psoriasis.","authors":"L Bertanha, N G Di Chiacchio, N Di Chiacchio, M L Cintra","doi":"10.1111/jdv.20414","DOIUrl":"https://doi.org/10.1111/jdv.20414","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus versus discordance in the classification of borderline melanocytic lesions between dermatopathologists and artificial intelligence: An Australian cohort study.","authors":"Nicholas M Muller, Chantal Rutjes, Samuel X Tan, Nisal Vipulaguna, Ayooluwatomiwa Oloruntoba, Toan Nguyen, Lena von Schuckmann, Brigid Betz-Stablein, Kiarash Khosrotehrani, Zongyuan Ge, H Peter Soyer, Ian Katz","doi":"10.1111/jdv.20412","DOIUrl":"https://doi.org/10.1111/jdv.20412","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancement of sun-damaged skin qualities with tirbanibulin: A prospective Phase 4 study (SunDamage Study).","authors":"Daisy Kopera","doi":"10.1111/jdv.20416","DOIUrl":"https://doi.org/10.1111/jdv.20416","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoural programmed cell death protein expression in 92 patients with atypical fibroxanthoma and pleomorphic dermal sarcoma.","authors":"Thilo Gambichler, Emilia Sorescu, Fahimeh Razeghpour, Jürgen C Becker, Laura Susok","doi":"10.1111/jdv.20421","DOIUrl":"https://doi.org/10.1111/jdv.20421","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis'.","authors":"Ankur Kapoor, Rachana Mehta, Muhammed Shabil, Sanjit Sah","doi":"10.1111/jdv.20394","DOIUrl":"https://doi.org/10.1111/jdv.20394","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.","authors":"Z Apalla, A Freites-Martinez, K Grafanaki, A Ortiz-Brugues, V Nikolaou, D Fattore, P Sollena, S Deverapalli, S Babakoohi, A Galimont, N Kluger, M Beylot-Barry, C Larocca, C Iriarte, J Smith, I Tattersall, R Dodiuk-Gad, M Sauder, C Carrera, B Kwong, M Whitley, N Leboeuf, P Romano, M Starace, V Mateeva, J Riganti, J Hirner, A B Patel, C M Reyes-Habito, L Kraehenbuehl, M Kheterpal, M Fida, J Hassel, M Lacouture, V Sibaud","doi":"10.1111/jdv.20391","DOIUrl":"https://doi.org/10.1111/jdv.20391","url":null,"abstract":"<p><strong>Background: </strong>There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.</p><p><strong>Objective: </strong>To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.</p><p><strong>Methods: </strong>The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi-induced acneiform rash. Experts responded to an anonymous 5-point Likert scale survey. The coordinators collected the first-round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second-round survey.</p><p><strong>Results: </strong>Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low-dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid-sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.</p><p><strong>Conclusion: </strong>This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute urticaria management: Gaps, challenges and the need for further evidence","authors":"Emek Kocatürk,&nbsp;Marcus Maurer","doi":"10.1111/jdv.20320","DOIUrl":"10.1111/jdv.20320","url":null,"abstract":"&lt;p&gt;The recent systematic review published in JEADV by Badloe et al&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; provides a comprehensive analysis of the management for acute urticaria (AU) with corticosteroids, highlighting the persistent uncertainties surrounding the use of systemic corticosteroids in conjunction with antihistamines. This article offers valuable insights into the current practices and evidence-based approaches, yet it underscores significant gaps that necessitate further research.&lt;/p&gt;&lt;p&gt;Despite limited robust evidence supporting their efficacy, corticosteroids are conventionally and widely used in the treatment of AU. The contrasting findings from the studies included in this review reflect the clinical conundrum faced by healthcare providers: while corticosteroids are commonly employed to manage AU, their benefits in conjunction with antihistamines remain unsubstantiated in many cases. For instance, out of four RCTs which assessed the efficacy of corticosteroids in addition to antihistamines for the management of AU, two studies revealed that a combination of corticosteroids and antihistamines did not have a beneficial effect on the resolution of AU, while the other two found a positive effect.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The effect of corticosteroids in the management of urticaria has been recently evaluated in a systematic review by Chu et al&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; which provided moderate certainty of evidence that systemic corticosteroids likely improve urticaria activity in patients who do not respond well to antihistamines alone; however, systemic corticosteroids likely increase the risk of adverse effects such as GI discomfort and neuropsychiatric changes, with an odds ratio (OR) of 2.76. As a result, it is concluded that the addition of corticosteroids to an antihistamine as a treatment option for AU and to assess long-term outcomes of corticosteroid treatment needs to be further investigated.&lt;/p&gt;&lt;p&gt;The article also highlights a critical issue: the reliance on older treatment modalities, such as first-generation antihistamines, which are still prevalent in many emergency departments. The sedative properties and other adverse effects of these drugs, particularly diphenhydramine, raise concerns about their continued use when less sedative and rapid acting options like cetirizine are available. The finding that intravenous cetirizine is as effective as diphenhydramine, with fewer side effects, suggests a potential shift in treatment protocols that could enhance patient outcomes and safety.&lt;/p&gt;&lt;p&gt;The review also brings to light the current gaps of knowledge in AU such as the potential for AU to progress to chronic spontaneous urticaria (CSU) and whether corticosteroids might influence this progression. Previous reports show that average duration of AU is ≤1 week and the rates of progression of AU to CSU are between 5% and 39%.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Two previous studies tried to identify the factors that are linked to the progression of AU to ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2047-2048"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining treat-to-target principles with patient choice: A small step AHEAD in the right direction","authors":"Hywel C. Williams","doi":"10.1111/jdv.20298","DOIUrl":"10.1111/jdv.20298","url":null,"abstract":"&lt;p&gt;The treat-to-target approach specifies optimum treatment targets such as blood glucose levels that result in health benefit. Setting single targets for complex inflammatory conditions such as atopic dermatitis (AD) is challenging, and depends on which disease aspects disease are considered to be important, by whom, along with how and when to measure them. A criticism of treat-to-target is its one-size-fits-all approach. Patients/carers may have different preferences on what is important for them, and what is a worthwhile gain when traded-off against the harms and inconvenience of particular treatments.&lt;/p&gt;&lt;p&gt;To address these limitations of a treat-to-target approach, the AHEAD (Aiming High in Eczema/Atopic Dermatitis) international group sought to identify &lt;i&gt;what&lt;/i&gt; aspects of atopic dermatitis (AD) might be included in a treat-to-target approach and &lt;i&gt;how&lt;/i&gt; they might be measured.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The group's previous survey identified the most significant symptoms for adult AD patients, how they are measured and treatment expectations. The group used that data to draft a series of treatment recommendations that were subject to a Delphi survey involving 77 AD experts. Unusually, consensus was reached for all 34 recommendations after just one voting round. The group suggest that patients should identify between one to three from six features selected by the AD experts (itch, skin appearance, sleep disturbance, mental health, skin pain and daily life impact). The clinician also chooses an additional objective assessment of disease control. Targets for both optimal and moderate control are suggested for these outcomes for 3–6 months, and monitored with a recommended instrument chosen by the clinician.&lt;/p&gt;&lt;p&gt;What I liked about this initiative was the attempt to combine the best of both worlds—retaining more ambitious treatment targets for people with AD with some input from patients on what to measure and how. The proposed outcomes align with clinical practice outcomes from the Harmonising Outcomes Measures for Eczema (HOME) initiative.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; I also liked the flexibility for moderate as well as optimal control.&lt;/p&gt;&lt;p&gt;What was missing was lack of consideration of other crucial aspects that govern treatment choices for patients including adverse effects, inconvenience, access and costs. Although adverse effects may be treatment-specific, balancing benefits and harms is a mandatory part of shared decision-making as exemplified in AD patient decision aids.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The preceding adult patient qualitative work, sponsored by AbbVie and cited only in abstract form, was useful but limited, as young people and children/carers where AD is commonest were not included. Although the adult qualitative study was considered when drafting the initial AHEAD recommendations, the complete absence of patient/carer involvement in the final recommendations was disappointing. Other initiatives such as HOME have found that ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2051-2052"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}